Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Nda Submission March 2026 Fda Review Timeline

As of March 2026, there has been no Retatrutide NDA submission, despite some online rumors.[1] Eli Lilly's investigational triple agonist shows promise with up to 28.7% weight loss in Phase 3 trials,[2] but full data from the TRIUMPH program is needed before filing.[3] The Retatrutide NDA submission March 2026 FDA review timeline points to a late 2026 or early 2027 filing, followed by 6-12 months of FDA review for potential approval in 2027-2028.[4]

What Is Retatrutide and Why the Buzz Around Its NDA?

Retatrutide has generated excitement as a next-generation obesity treatment. Developed by Eli Lilly,[1] it targets multiple hormones to drive superior weight loss compared to current options. The buzz stems from its potential to reshape the market, especially with the Retatrutide NDA submission March 2026 FDA review timeline drawing investor interest.

Retatrutide: Eli Lilly's Triple Receptor Agonist Explained

Retatrutide, also known as LY3437943, is an investigational drug given as a weekly injection.[3] It acts as a triple agonist, meaning it activates three key receptors: GLP-1, GIP, and glucagon.[2] This multi-target approach aims to boost metabolism, reduce appetite, and burn fat more effectively than single or dual agonists.

Eli Lilly is advancing it through late-stage trials as part of their broad Eli Lilly's obesity drug portfolio. Early results suggest it could offer life-changing benefits for obesity and type 2 diabetes patients.

Targeting GLP-1, GIP, and Glucagon Receptors for Obesity and Diabetes

The GLP-1 receptor helps control blood sugar and appetite, similar to drugs like Ozempic. GIP enhances insulin release and fat metabolism, while glucagon promotes energy use from fat stores. Together, they create a powerful synergy for weight management.[2]

In obesity trials, patients need a BMI of 30 or higher, or 27+ with conditions like hypertension.[3] This targets those who struggle with standard treatments. For more on the hormone pathways, see ClinicalTrials.gov listings for Retatrutide.

Comparison to Existing GLP-1 Drugs Like Semaglutide

Retatrutide builds on GLP-1 agonists like semaglutide, which achieve about 15-20% weight loss. Phase 2 data showed Retatrutide delivering up to 24% loss, outpacing semaglutide's STEP trials.[2] Its glucagon addition may preserve muscle better during weight loss.

However, Retatrutide is still experimental. Semaglutide is FDA-approved and widely available, while Retatrutide awaits full validation.[1]

Retatrutide NDA Submission Status as of March 2026

Confusion online has sparked questions about a March 2026 filing, but official updates confirm no NDA yet.[1] Eli Lilly needs comprehensive Phase 3 results to submit.[3] The Retatrutide NDA submission March 2026 FDA review timeline remains speculative without new announcements.

No NDA Filed in March 2026: Addressing Conflicting Reports

Most credible sources, including Lilly's investor updates, state no filing occurred by March 2026.[1] One outlier report claimed submission and review, but it lacks backing from FDA or Lilly sites. Always check primary sources like Lilly's pipeline page for accuracy.

Requirements for NDA Submission: Phase 3 Data and Beyond

An NDA requires thousands of pages on safety, efficacy, manufacturing, and labeling.[4] Retatrutide needs data from all seven TRIUMPH trials,[3] plus long-term follow-up. Preclinical studies and risk assessments round out the package, per FDA NDA guidelines.

Projected Filing Timeline: Late 2026 to Early 2027

Analysts project filing after 2026 data readouts.[1] Diabetes indications might file first, followed by obesity. Delays could push to 2027 if trials extend.

FDA Review Timeline for Retatrutide NDA

Once filed, the FDA's clock starts after a 60-day acceptance review.[4] Timelines vary by review type and data quality. The Retatrutide NDA submission March 2026 FDA review timeline hinges on when filing happens, likely post-2026.

Standard vs. Priority Review: 10-12 Months or 6 Months?

Standard review takes 10 months from acceptance, totaling about 12 months overall.[4] Priority review, for breakthrough drugs, cuts it to 6 months. Retatrutide's strong efficacy (28.7% weight loss) could qualify it, similar to tirzepatide.[2]

Learn more about the FDA NDA process.

60-Day Acceptance Period and Full Review Process

First, FDA checks if the NDA is complete. If accepted, review teams analyze trials, inspect sites, and advise on labeling. Advisory committees (AdCom) may weigh in for complex cases.

Factors Influencing Review Speed: Safety and Efficacy Data

Clean safety data and met endpoints speed things up. Issues like new side effects could trigger holds. Obesity drugs often get priority due to unmet needs.

Review Type	Time from Acceptance	Total Timeline (est.)
Standard	10 months	12 months
Priority	6 months	8 months

Clinical Trial Status: TRIUMPH Phase 3 Program Update

The TRIUMPH program includes seven trials testing Retatrutide in obesity, diabetes, sleep apnea, and more.[3] Most are ongoing, with key readouts expected in 2025-2026. This data will support the Retatrutide NDA submission March 2026 FDA review timeline.

Overview of 7 Ongoing TRIUMPH Trials

Trials cover monotherapy in obesity (no diabetes), combo therapy, and special populations. Durations reach 109 weeks, including follow-up. See details on obesity clinical trials and ClinicalTrials.gov.

TRIUMPH-4 Results: 28.7% Weight Loss Milestone

TRIUMPH-4 hit its mark with 28.7% mean weight loss at highest dose.[2] This tops tirzepatide comparison results of 26% in SURMOUNT-5. A1C dropped 2%, showing diabetes benefits too.

Trial Eligibility: BMI ≥30 or ≥27 with Comorbidities

Participants are adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus issues like high blood pressure.[3] Exclusion criteria include certain cancers or pancreatitis history.

Completion Projections: 2025-2026 Data Readouts

Most primaries end in 2025, with full data by 2026. This aligns with NDA prep.[1]

Efficacy Results: Phase 2 and Phase 3 Highlights

Retatrutide shines in weight loss and metabolic improvements. Phase 2 set records; Phase 3 confirms them. These fuel optimism for the Retatrutide NDA submission March 2026 FDA review timeline.

Phase 2: Up to 24% Weight Loss Over 48 Weeks

In a 338-patient trial, 12mg dose led to 24.2% loss vs. 2.1% placebo. Published in NEJM.[2] Higher than semaglutide (15%) or tirzepatide (21%).

Compare to tirzepatide comparison.

Phase 3 Efficacy: Weight Loss, A1C Reduction, and More

TRIUMPH-4: 28.7% loss, surpassing goals.[2] Other trials show similar trends in diabetes and osteoarthritis.

Benefits Beyond Weight Loss: Lipids, Blood Pressure, Glycemic Control

Improves cholesterol, lowers BP by 7-10 mmHg, and sustains A1C under 7%. Muscle preservation noted due to glucagon.

Weight loss: 24-29% at 72-104 weeks
A1C: -2.02%
Lipids: Triglycerides down 30%

Safety Data and Side Effects Profile

Safety mirrors the GLP-1 class, with good tolerability.[2] No major red flags in trials to date. This supports smooth progress in the Retatrutide NDA submission March 2026 FDA review timeline.

Manageable Side Effects Similar to GLP-1 Agonists

Most issues are mild-moderate GI: nausea (50%), vomiting (30%), diarrhea. They peak early and fade with dose escalation.

No New Safety Signals in Phase 2/3 Trials

No increases in pancreatitis, gallbladder events, or thyroid tumors vs. comparators. Heart rate rises mildly (5-10 bpm).[3]

Details on common weight loss drug side effects.

GI Issues and Other Common Effects: What to Expect

Nausea: 49% (vs. 14% placebo)
Vomiting: 32%
Diarrhea: 25%
Injection site reactions: <5%

Ongoing Monitoring in Long-Term Trials (109 Weeks)

Long-term arms track CV safety, bone health, and cancer risk. Interim data reassuring.

Approval Scenarios and Projections

Timelines depend on filing date and review path. Best case eyes 2027 launch.

Best Case: Late 2026 Filing, Mid-2027 Approval

Priority review + clean data = Q2 2027 decision. Diabetes first.[4]

Realistic Timeline: 2027-2028 Launch

Standard review post-full obesity data.

Delayed Scenario: 2029+ with Additional Studies

If safety issues or manufacturing snags arise.

Key Dependencies: Clean Data and No AdCom Delays

Scenario	NDA Filing	FDA Decision	Assumptions
Best	Late 2026	Mid-2027	Priority, 28.7% data
Realistic	2026-2027	2028	Standard review
Delayed	2027+	2029+	Extra trials

Legal Status and Availability in March 2026

Retatrutide is investigational only—no prescriptions.[1] It remains strictly controlled under FDA regulations, with no pathway for general use until approval.

Not FDA Approved: Investigational Only

No approval by FDA, EMA, or others as of March 2026.[1] It is classified as an experimental drug in Phase 3 development.

Restricted to Clinical Trials—No Prescription Access

Access is limited to authorized clinical trial participants only. There are no expanded access or compassionate use programs reported, and physicians cannot prescribe it off-label.

Global Status: No EMA or Other Approvals Yet

While trials run internationally, no regulatory approvals exist outside the U.S. pathway. EMA timelines would likely follow FDA closely.

Research Use Warning: Not for Human Consumption

Online vendors may sell "research-grade" Retatrutide, but these are unregulated compounding products unsafe for human use. The FDA warns against such purchases due to contamination risks, inaccurate dosing, and legal violations. Stick to official trial enrollment for safe access.

Sourcing research‑grade retatrutide?

Ready to explore medical weight management?